nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00068003,Cell Harvest and Preparation for Surgery Branch Treatment Protocols,,Enrolling by invitation,Observational,Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small Cell Lung Cancer,Anti-CD19 CAR PBL,,National Cancer Institute (NCI),,7000,2003-09-08,,United States,No,https://clinicaltrials.gov/study/NCT00068003
NCT01595074,"The Identification, Validation and Implemention of Prognostic and/or Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)",,Not yet recruiting,Observational,Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer,medical chart review; laboratory biomarker analysis,,National Cancer Institute (NCI),,950,2012-05-05,,Canada,No,https://clinicaltrials.gov/study/NCT01595074
NCT02178163,A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.,Not Applicable,Recruiting,Interventional,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cytology specimen collection procedure; laboratory biomarker analysis,,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),1020,2014-08-01,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT02178163
NCT02596490,Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners,Not Applicable,Recruiting,Interventional,Lung Cancer,Questionnaires; Meditation and Discussion Sessions; Cancer-Related Discussion Program,,M.D. Anderson Cancer Center,"National Cancer Institute (NCI); American Cancer Society, Inc.",300,2016-04-06,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT02596490
NCT03260491,"A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP); HER3-DXd (CTM-3 Lyo-DP),,Daiichi Sankyo,Merck Sharp & Dohme LLC,309,2017-10-30,2026-12-31,Japan; Netherlands; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT03260491
NCT03586453,A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Osimertinib,,Dana-Farber Cancer Institute,AstraZeneca,30,2018-08-13,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT03586453
NCT03774758,Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening,,Recruiting,Observational,Nodule Solitary Pulmonary; Non-small Cell Lung Cancer,Guardant Health ct-DNA LUNAR assay,,"University of California, San Francisco","Northern California Institute of Research and Education; Guardant Health, Inc.",590,2017-12-17,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT03774758
NCT03948100,"Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",Not Applicable,Recruiting,Interventional,Esophageal Carcinoma; Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Educational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Yoga,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),400,2018-12-20,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03948100
NCT04093167,"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pembrolizumab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; Personal Genome Diagnostics; Mark Foundation for Cancer Research",230,2020-05-26,2027-07-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT04093167
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04151342,CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS),,Recruiting,Observational,"Cancer; Malignancies Multiple; Malignant Solid Tumor; Cancer, Therapy-Related; Molecular Sequence Variation; Genetic Alteration; Gene Fusion; Receptor Tyrosine Kinase Gene Mutation; RTK Family Gene Mutation; Ras (Kras or Nras) Gene Mutation",Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.; Patient-reported outcomes (PROs),,"University Health Network, Toronto","Takeda Canada, Inc.; Applied Health Research Centre; Programs for Assessment of Technology in Health Research Institute; AstraZeneca; Amgen; Bayer; Nuvation Bio Inc.; IQVIA Solutions Canada Inc.",5500,2020-01-17,2029-12-05,Canada,No,https://clinicaltrials.gov/study/NCT04151342
NCT04253964,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,Phase 2,Recruiting,Interventional,Nonsmall Cell Lung Cancer; Performance Status,"Pembrolizumab; Carboplatin; Paclitaxel; Nab paclitaxel; Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13); QLQ-C30 Global Health/Quality of Life Questionnaire; COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes; Pemetrexed",,Wake Forest University Health Sciences,National Cancer Institute (NCI),80,2020-07-01,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT04253964
NCT04300556,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,Farletuzumab ecteribulin; Prednisone; Prednisolone; Dexamethasone; Lenvatinib,,Eisai Inc.,,182,2020-08-06,2030-08-08,France; Japan; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04300556
NCT04302025,"NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib,,"Genentech, Inc.",,99,2020-11-06,2030-05-30,United States,No,https://clinicaltrials.gov/study/NCT04302025
NCT04317534,A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153,Phase 2,Recruiting,Interventional,"NSCLC, Stage I",Pembrolizumab,,"Greg Durm, MD",Merck Sharp & Dohme LLC,244,2020-05-05,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT04317534
NCT04486833,"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",quaratusugene ozeplasmid; osimertinib; Platinum-Based Chemotherapy,,"Genprex, Inc.",,158,2021-09-03,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT04486833
NCT04585477,Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E),Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy,,Stanford University,AstraZeneca,80,2021-04-08,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT04585477
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Phase 2,Recruiting,Interventional,Solid Tumors,Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib,,Hoffmann-La Roche,,920,2021-01-18,2032-09-25,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; New Zealand; Poland; Portugal; Puerto Rico; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04589845
NCT04613596,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2/Phase 3,Recruiting,Interventional,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab,,Mirati Therapeutics Inc.,,806,2020-12-02,2029-10-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Georgia; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Norway; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04613596
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04762199,"A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Flt3/MerTK Inhibitor MRX-2843; Osimertinib,,Emory University,National Cancer Institute (NCI),69,2021-02-24,2026-12-27,United States,No,https://clinicaltrials.gov/study/NCT04762199
NCT04852588,Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR),Not Applicable,Recruiting,Interventional,Non-Small Cell Lung Cancer,Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA); Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA),,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,Academic Medical Organization of Southwestern Ontario,29,2021-11-09,2025-05-31,Canada,No,https://clinicaltrials.gov/study/NCT04852588
NCT04929223,"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",Phase 1,Recruiting,Interventional,Metastatic Colorectal Cancer,Inavolisib; Bevacizumab; Cetuximab; Atezolizumab; Tiragolumab; SY-5609; Divarasib; FOLFOX; FOLFIRI; FoundationOne®Liquid CDx,,Hoffmann-La Roche,,542,2021-10-22,2028-11-07,Australia; Canada; Denmark; Germany; Italy; Poland; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04929223
NCT04956640,A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms",LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin,,Eli Lilly and Company,Merck Sharp & Dohme LLC,540,2021-07-19,2027-04-05,Australia; Canada; France; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04956640
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,MK-1084; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil,,Merck Sharp & Dohme LLC,,830,2021-12-17,2030-02-25,Australia; Canada; Chile; China; Denmark; Israel; Italy; Japan; Lithuania; Malaysia; New Zealand; Panama; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05067283
NCT05074810,A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; KRAS Activating Mutation,avutometinib and sotorasib; avutometinib and sotorasib and defactinib,,"Verastem, Inc.",Amgen,153,2022-04-12,2027-04-05,Belgium; France; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05074810
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05261399,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",Phase 3,Recruiting,Interventional,Carcinoma; Non-Small-Cell Lung,Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin,,AstraZeneca,,324,2022-08-03,2026-12-17,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Netherlands; Philippines; Poland; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05261399
NCT05332925,Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN),,Recruiting,Observational,Lung Cancer; NSCLC; NSCLC Stage IV,Standard of care immune checkpoint inhbitors,,"Jun Zhang, MD, PhD",Nilogen Oncosystems,25,2022-07-21,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05332925
NCT05410145,"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,KRAS P.G12C,D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab,,"D3 Bio (Wuxi) Co., Ltd",,442,2022-08-03,2027-04-05,Australia; China; France; Germany; Hong Kong; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05410145
NCT05419375,Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors,Phase 2,Recruiting,Interventional,Solid Tumors,Screening platform,,Hoffmann-La Roche,,15000,2022-07-22,2032-12-22,Australia; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; France; Germany; Hong Kong; India; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Serbia; Singapore; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05419375
NCT05500092,"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Nivolumab; (8gy x 3); Platinum Doublet,,Montefiore Medical Center,Bristol-Myers Squibb,52,2023-01-25,2025-07-05,United States,No,https://clinicaltrials.gov/study/NCT05500092
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05609578,A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced NSCLC; Metastatic Lung Cancer,Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin,,Mirati Therapeutics Inc.,,90,2022-11-22,2026-12-01,Brazil; Chile; France; Georgia; Greece; Hungary; Italy; Malaysia; Poland; Serbia; Spain; Switzerland; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05609578
NCT05638295,A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial,Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Panitumumab; Sotorasib,,National Cancer Institute (NCI),,105,2024-08-01,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05638295
NCT05642572,"A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",Phase 2,Recruiting,Interventional,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Capmatinib; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Ramucirumab,,SWOG Cancer Research Network,National Cancer Institute (NCI),66,2023-05-05,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT05642572
NCT05669846,Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Healthy Donor Fecal Microbiota Transplant (hdFMT); Pembrolizumab,,Diwakar Davar,Gateway for Cancer Research,26,2025-01-08,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT05669846
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05789082,"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed,,Hoffmann-La Roche,,320,2023-06-20,2032-01-29,Argentina; Australia; Belgium; Brazil; Canada; China; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05789082
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05845671,"A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",Phase 1/Phase 2,Recruiting,Interventional,Lung Cancer; Non Small Cell Lung Cancer,Amivantamab 1050mg; Amivantamab 1400mg; Amivantamab (to be determined); Amivantamab (to be determined),,"University of Colorado, Denver","Janssen Research & Development, LLC",12,2023-07-17,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT05845671
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05892068,Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Tucatinib,,Memorial Sloan Kettering Cancer Center,Pfizer; Seagen Inc.,28,2023-05-09,2028-05-09,United States,No,https://clinicaltrials.gov/study/NCT05892068
NCT05920356,"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),Sotorasib; Pembrolizumab,,Amgen,,750,2023-11-16,2031-06-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05920356
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06124118,A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC,Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer,carboplatin chemotherapy; NovoTTF-200T (TTFields) System; Durvalumab,,University of Utah,,30,2024-04-04,2026-11-15,United States,No,https://clinicaltrials.gov/study/NCT06124118
NCT06128551,"Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Assigned interventions,,"Revolution Medicines, Inc.",,210,2023-11-14,2026-11-30,France; Germany; Italy; Netherlands; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06128551
NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib; Olaparib,,M.D. Anderson Cancer Center,Mirati Therapeutics Inc.,52,2024-01-30,2030-08-25,United States,No,https://clinicaltrials.gov/study/NCT06130254
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06225804,"A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,ABSK112,,"Abbisko Therapeutics Co, Ltd",,164,2024-02-22,2028-03-05,China; United States,No,https://clinicaltrials.gov/study/NCT06225804
NCT06244771,"An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer",FMC-376,,Frontier Medicines Corporation,,403,2024-02-12,2028-04-05,Australia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06244771
NCT06248606,Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Adagrasib; Stereotactic Radiosurgery,,"Ryan Gentzler, MD",Mirati Therapeutics Inc.; University of Virginia,30,2024-08-06,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06248606
NCT06249282,A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy; Biospecimen Collection; Carfilzomib; Computed Tomography; Echocardiography; Magnetic Resonance Imaging; Sotorasib,,City of Hope Medical Center,National Cancer Institute (NCI),15,2024-04-24,2026-03-19,United States,No,https://clinicaltrials.gov/study/NCT06249282
NCT06252129,Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens,Not Applicable,Recruiting,Interventional,Lung Cancer; Lymph Node Metastasis; Pathologic Processes,Subjects undergoing a lung specimen lymph node dissection; Control group,,Brigham and Women's Hospital,,160,2024-07-26,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06252129
NCT06252649,"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",Phase 3,Recruiting,Interventional,Metastatic Colorectal Cancer,FOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb,,Amgen,,450,2024-07-17,2031-08-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06252649
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06312137,A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery,Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication,,Merck Sharp & Dohme LLC,,780,2024-04-03,2034-10-23,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Romania; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06312137
NCT06333951,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",Phase 1,Recruiting,Interventional,Thoracic Tumors; Non-small Cell Lung Cancer,AMG 193; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib,,Amgen,,500,2024-09-17,2031-10-27,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06333951
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06345729,"A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Placebo; Pembrolizumab,,Merck Sharp & Dohme LLC,,600,2024-05-24,2031-02-18,Argentina; Australia; Austria; Brazil; Bulgaria; Canada; Chile; China; France; Georgia; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; New Zealand; Philippines; Poland; Romania; South Korea; Spain; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06345729
NCT06385262,"Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Alirocumab; Cemiplimab; Chemotherapy,,Duke University,Regeneron Pharmaceuticals,126,2025-03-17,2029-10-30,United States,No,https://clinicaltrials.gov/study/NCT06385262
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06403436,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Adult Solid Tumor; Adult Disease; Cancer; NSCLC; EGFR; KRAS G12C; Squamous Cell Lung Cancer,TT125-802,,TOLREMO therapeutics AG,,50,2023-11-07,2026-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06403436
NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; KRAS G12C Mutations,Cetuximab; Cemiplimab; Adagrasib,,M.D. Anderson Cancer Center,,31,2024-08-28,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT06412198
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab; sac-TMT; Carboplatin; Paclitaxel; Nab-paclitaxel,,Merck Sharp & Dohme LLC,,851,2024-06-10,2031-02-12,Argentina; Austria; Brazil; Canada; Chile; China; Colombia; Czechia; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Peru; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06422143
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06545331,A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer; NSCLC (Non-small Cell Lung Cancer); Hormone-receptor-positive Breast Cancer; Triple Negative Breast Cancer (TNBC),XB010; Pembrolizumab,,Exelixis,,396,2024-08-06,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT06545331
NCT06561386,"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin,,Bristol-Myers Squibb,,1000,2024-10-07,2032-08-04,Argentina; Australia; Austria; Belgium; Brazil; Chile; China; Colombia; Denmark; France; Germany; India; Ireland; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Romania; Saudi Arabia; South Africa; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06561386
NCT06566443,Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Honokiol,,The Methodist Hospital Research Institute,,15,2024-11-08,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT06566443
NCT06582771,A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Non Small Lung Cancer,Sotorasib,,Memorial Sloan Kettering Cancer Center,,39,2024-08-30,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT06582771
NCT06593522,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,MTAP-deleted NSCLC,AMG 193,,Amgen,,200,2024-12-26,2030-11-29,Australia; Brazil; Canada; China; Czechia; Hong Kong; Japan; Latvia; Netherlands; Portugal; Singapore; South Korea; Switzerland; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06593522
NCT06602661,A Prospective Randomized Study of Reinforced Vs Non-reinforced Staple Lines in Fissureless Lobectomy,Phase 1,Not yet recruiting,Interventional,"Lung; Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Lung Cancer, Non-Small Cell; Lung Carcinoma; Lobectomy; Lobectomy Patient; Lobectomy by Video-thoracoscopies; VATS",Fissureless Lobectomy with Reinforced Staple Lines; Fissureless Lobectomy with Non-Reinforced Staple Lines,,Surrey Thoracic Surgery Group,Johnson and Johnson Medical,65,2025-01-01,2028-01-05,Canada,No,https://clinicaltrials.gov/study/NCT06602661
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06671613,Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer,Not Applicable,Recruiting,Interventional,Stage IV NSCLC; NSCLC; Immunotherapy; Fasting Mimicking Diet,FMD; Regular Diet Plus FMD,,VA Office of Research and Development,Indiana University; US Department of Veterans Affairs Cooperative Studies Program; L-Nutra Inc,66,2025-10-27,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT06671613
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06712745,Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung,Early Phase 1,Recruiting,Interventional,"Cancer, Lung; Metastasis",Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR),,University of Texas Southwestern Medical Center,Elekta Limited,30,2025-09-19,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06712745
NCT06720987,"A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations",Phase 1,Recruiting,Interventional,KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer),KQB365; Cetuximab,,Kumquat Biosciences Inc.,,128,2025-02-04,2030-06-30,United States,No,https://clinicaltrials.gov/study/NCT06720987
NCT06793215,"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin,,Hoffmann-La Roche,Chugai Pharmaceutical,600,2025-10-24,2030-10-31,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Hungary; Italy; Netherlands; New Zealand; Poland; Portugal; Singapore; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06793215
NCT06804824,"A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,VVD-159642; Sotorasib; Trametinib,,"Vividion Therapeutics, Inc.",,220,2025-02-25,2027-08-01,Australia; United States,No,https://clinicaltrials.gov/study/NCT06804824
NCT06807619,BrainMet ADePPT (Anticancer Drug Penetration Platform Trial),Phase 1,Recruiting,Interventional,Brain Tumor,Sotorasib,,Memorial Sloan Kettering Cancer Center,Amgen,16,2025-01-29,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT06807619
NCT06814496,RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3,Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer; Merkel Cell Carcinoma,Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy,,University of Arizona,Amgen,30,2025-09-08,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT06814496
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin,,Mirati Therapeutics Inc.,,630,2025-04-24,2032-04-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06875310
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",Phase 3,Recruiting,Interventional,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib; docetaxel,,"Revolution Medicines, Inc.",,420,2025-05-06,2030-12-01,Australia; Belgium; France; Germany; Hong Kong; Ireland; Italy; Japan; Netherlands; Poland; Puerto Rico; Singapore; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06881784
NCT06890598,"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Olomorasib; Pembrolizumab; Durvalumab; Placebo,,Eli Lilly and Company,AstraZeneca,700,2025-03-27,2032-02-05,Australia; Austria; Belgium; Brazil; Chile; China; Czechia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06890598
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06973564,"A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,JAB-23E73; JAB-23E73; JAB-23E73,,"Jacobio Pharmaceuticals Co., Ltd.",,294,2025-05-29,2028-02-05,United States,No,https://clinicaltrials.gov/study/NCT06973564
NCT06997497,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)",Phase 3,Recruiting,Interventional,Colon Adenocarcinoma; Rectal Adenocarcinoma,MK-1084; Oxaliplatin; Leucovorin/levofolinate calcium; 5-Fluorouracil; Cetuximab; Bevacizumab; Bevacizumab biosimilar,,Merck Sharp & Dohme LLC,,477,2025-07-16,2030-10-27,Argentina; Australia; Brazil; China; Finland; France; Germany; Hong Kong; Israel; Japan; Netherlands; Poland; Romania; South Korea; Spain; Taiwan; Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06997497
NCT07012031,"A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Sotorasib; Trastuzumab Deruxtecan,,National Cancer Institute (NCI),,37,2026-08-07,2027-06-14,Canada,No,https://clinicaltrials.gov/study/NCT07012031
NCT07094204,A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications,Phase 1,Recruiting,Interventional,Solid Tumor; Non-Small-Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer,ASP5834; panitumumab,,Astellas Pharma Inc,,364,2025-07-25,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT07094204
NCT07132918,The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers,Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer (Stage III); Esophageal Cancer Stage I-III; Esophagogastric Cancer Stage I-III; Thymoma and Thymic Carcinoma Stage II-III; Other Cancers in the Thoracic Region,MRgART; LINAC,,"University of Wisconsin, Madison","National Heart, Lung, and Blood Institute (NHLBI)",60,2025-10-08,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT07132918
NCT07155187,Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI,Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Telisotuzumab Adizutecan; Standard of Care,,AbbVie,,430,2025-12-10,2030-09-05,Australia; Israel; Japan; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT07155187
NCT07190248,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Pembrolizumab (+) Berahyaluronidase alfa; Pemetrexed; Cisplatin; Carboplatin,,Merck Sharp & Dohme LLC,,675,2025-10-08,2032-08-06,Australia; Hungary; Israel; Japan; Romania; South Korea; Spain; Taiwan; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT07190248
NCT07209111,"A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)",Phase 2,Recruiting,Interventional,Neoplasm Malignant,MK-1084; Cetuximab,,Merck Sharp & Dohme LLC,,150,2025-12-04,2032-04-09,Denmark; Norway; South Korea; Spain; Sweden; United States,No,https://clinicaltrials.gov/study/NCT07209111
NCT07227025,A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Amivantamab; Olomorasib,,"Janssen Research & Development, LLC",,60,2025-12-22,2028-11-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT07227025
NCT07288034,Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP),Phase 2,Not yet recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Adagrasib; Anti-PD-L1 Monoclonal Antibody; Anti-PD1 Monoclonal Antibody; Bevacizumab; Biopsy Procedure; Biospecimen Collection; Chemotherapy; Computed Tomography; Durvalumab; Magnetic Resonance Imaging; Monitoring; Positron Emission Tomography; Surveillance; Tremelimumab,,City of Hope Medical Center,National Cancer Institute (NCI),535,2026-09-21,2028-09-22,United States,No,https://clinicaltrials.gov/study/NCT07288034
